High‐risk prostate cancer patients receiving primary ADT may develop rapid disease progression and benefit from early enrolment into clinical trials of novel androgen‐receptor targeted drugs, chemotherapy, radiopharmaceutical agent, immunotherapy or combination therapies. This evidence concerns the gene AR and prostate cancer.